Literature DB >> 30069903

Cytochrome P450 4A11 expression in tumor cells: A favorable prognostic factor for hepatocellular carcinoma patients.

Hyuk Soo Eun1,2, Sang Yeon Cho3, Byung Seok Lee1,2, Sup Kim4, In-Sang Song5,6, Kwangsik Chun5,6, Cheong-Hae Oh1,2, Min-Kyung Yeo7, Seok Hyun Kim1,2, Kyung-Hee Kim7.   

Abstract

BACKGROUND AND AIM: Elevated cytochrome p450 (CYP) 4A gene expression has been linked to the aggravation of various cancers and affects various regulated metabolites. In hepatocellular carcinoma (HCC), the clinicopathological value of CYP4A has not yet been explored, although CYP4A is expressed at high levels in the liver. The goal of this study was to evaluate the clinicopathological value of CYP4A11 expression in HCC.
METHODS: We performed immunohistochemical analysis of CYP4A11 and correlated the results with clinicopathological features of HCC (n = 155). Western blotting and reverse transcription-polymerase chain reaction against CYP4A11 and CYP4A22 were also performed for 15 and 20 pairs of fresh-frozen primary HCC and non-neoplastic liver tissue, respectively. Moreover, we analyzed the underlying mechanism by comparing the high and low CYP4A11 mRNA expression groups using gene set enrichment analysis.
RESULTS: CYP4A11 expression level was higher in non-neoplastic hepatocytes than those in HCC cells (P < 0.001), and CYP4A11 expression positively correlated with favorable prognostic factors, including tumor size, histological grade, and pathological tumor stage (P = 0.007, P = 0.005, and P = 0.007). Multivariate analysis revealed that CYP4A11 expression was an independent prognostic factor of overall and disease-free survival (P = 0.002 and P = 0.033). Based on gene set enrichment analysis, high CYP4A11 mRNA expression negatively correlated with the expression of cell cycle-related genes.
CONCLUSION: These findings support the notion that CYP4A11 expression is a favorable prognostic factor of HCC and suggest potential predictive diagnostic and prognostic roles of CYP4A11 expression in HCC.
© 2018 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  cytochrome P450 CYP4A11; diagnosis; hepatocellular carcinoma; prognosis

Mesh:

Substances:

Year:  2018        PMID: 30069903     DOI: 10.1111/jgh.14406

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  7 in total

1.  MetaOmGraph: a workbench for interactive exploratory data analysis of large expression datasets.

Authors:  Urminder Singh; Manhoi Hur; Karin Dorman; Eve Syrkin Wurtele
Journal:  Nucleic Acids Res       Date:  2020-02-28       Impact factor: 16.971

Review 2.  Targeting the eicosanoid pathway in hepatocellular carcinoma.

Authors:  Anshuli Razdan; Nathan M Main; Vincent Chiu; Nicholas A Shackel; Paul de Souza; Katherine Bryant; Kieran F Scott
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

3.  Integrated Proteomics and Bioinformatics to Identify Potential Prognostic Biomarkers in Hepatocellular Carcinoma.

Authors:  Qifan Zhang; Zhen Xiao; Shibo Sun; Kai Wang; Jianping Qian; Zhonglin Cui; Tao Tao; Jie Zhou
Journal:  Cancer Manag Res       Date:  2021-03-11       Impact factor: 3.989

4.  Development and Validation of a Metabolic-related Prognostic Model for Hepatocellular Carcinoma.

Authors:  Junyu Huo; Liqun Wu; Yunjin Zang
Journal:  J Clin Transl Hepatol       Date:  2021-02-22

5.  Elevated CXCL12 in the plasma membrane of locally advanced rectal cancer after neoadjuvant chemoradiotherapy: a potential prognostic marker.

Authors:  Sup Kim; Min-Kyung Yeo; Jun-Sang Kim; Ji-Yeon Kim; Kyung-Hee Kim
Journal:  J Cancer       Date:  2022-01-01       Impact factor: 4.207

6.  Immunohistochemical Expression of CD44, MMP-2, MMP-9, and Ki-67 as the Prognostic Markers in Non-Clear Cell Renal Cell Carcinomas-A Prospective Cohort Study.

Authors:  Magdalena Chrabańska; Magdalena Rynkiewicz; Paweł Kiczmer; Bogna Drozdzowska
Journal:  J Clin Med       Date:  2022-09-02       Impact factor: 4.964

7.  Identifying the Prognostic Risk Factors of Synaptojanin 2 and Its Underlying Perturbations Pathways in Hepatocellular Carcinoma.

Authors:  Rui Zhang; Wei-Jia Mo; Lan-Shan Huang; Ji-Tian Chen; Wei-Zi Wu; Wei-Ying He; Zhen-Bo Feng
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.